Human Insulin Inhalation Powder + Neutral protamine hagedorn insulin
Phase 2/3Completed 0 watching 0 views this week๐ Rising
65
Development Stage
โ
Pre-clinicalโ
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Type 2
Conditions
Diabetes Mellitus, Type 2
Trial Timeline
Jul 1, 2007 โ May 1, 2008
NCT ID
NCT00490854About Human Insulin Inhalation Powder + Neutral protamine hagedorn insulin
Human Insulin Inhalation Powder + Neutral protamine hagedorn insulin is a phase 2/3 stage product being developed by Eli Lilly for Diabetes Mellitus, Type 2. The current trial status is completed. This product is registered under clinical trial identifier NCT00490854. Target conditions include Diabetes Mellitus, Type 2.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00490854 | Phase 2/3 | Completed |
Competing Products
20 competing products in Diabetes Mellitus, Type 2